Moshe Ornstein, MD, MA

Articles

Dr Ornstein on the Use of IO/TKI Doublets in Non-ccRCC

September 6th 2024

Moshe Ornstein, MD, MA, discusses the use of first-line IO/TKI doublet regimens in patients with non–clear cell renal cell carcinoma.

Genetic Counseling for Patients with Non-Clear Cell RCC

April 26th 2023

The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.

Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

April 26th 2023

The panel discusses the best approaches to treating patients with non-clear cell RCC.

Preferred Treatment Regimens for Refractory RCC

April 19th 2023

The panel shares their preferred treatment regimens for patients with refractory renal cell carcinoma.

Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

April 19th 2023

Hans Hammers, MD, presents a profile of a 47-year-old male with refractory renal cell carcinoma.

Updates in the Adjuvant Treatment of Metastatic RCC

April 12th 2023

The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.

Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

April 5th 2023

Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.

Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

April 5th 2023

The panel provides an overview of novel double combination therapies currently under investigation.

Treatment Approaches for Patients with RCC and Bone Metastases

March 31st 2023

Mehmet Asim Bilen, MD, details how he approaches IO/TKI therapy for patients with renal cell carcinoma with bone metastases.

Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

March 31st 2023

The panel discusses the use of quality-of-life clinical trial data in metastatic renal cell carcinoma and how liver and brain metastases affect treatment decision-making.

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

March 23rd 2023

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

March 23rd 2023

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.

Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

March 15th 2023

Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.

Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

March 15th 2023

Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.

Dr. Ornstein on Enfortumab Vedotin in Advanced Urothelial Carcinoma

September 29th 2022

Moshe Ornstein, MD, MA, discusses the use of the antibody-drug conjugate enfortumab vedotin in patients with advanced urothelial carcinoma that is refractory to chemotherapy and immunotherapy.